# Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis

> **NCT02590588** · PHASE2 · TERMINATED · sponsor: **John Mark Sloan** · enrollment: 1 (actual)

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** Idelalisib

## Key facts

- **NCT ID:** NCT02590588
- **Lead sponsor:** John Mark Sloan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2017-03-27
- **Final completion:** 2017-03-27
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2017-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02590588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02590588, "Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02590588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*